Z
Zhao-Peng Liu
Researcher at Shandong University
Publications - 67
Citations - 951
Zhao-Peng Liu is an academic researcher from Shandong University. The author has contributed to research in topics: Chemistry & Histone deacetylase. The author has an hindex of 15, co-authored 63 publications receiving 720 citations. Previous affiliations of Zhao-Peng Liu include Chinese Ministry of Education.
Papers
More filters
Journal ArticleDOI
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
TL;DR: Based on their different zinc binding groups (ZBGs), HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur containing ZBG based derivatives and other ZBG-derived compounds, and their enzymatic inhibitory activity, selectivity and other biological activities are introduced and summarized.
Journal ArticleDOI
Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
TL;DR: This review makes a summary of the small-molecule VDAs in clinical developments and highlights some potential VDA leads or candidates for the treatment of tumors.
PatentDOI
Design, synthesis, and biological evaluation of 1-methyl-1, 4-dihyrdoindeno[1,2-C]pyrazole analogues as potential anticaner agents targeting tubulin colchicine binding site
TL;DR: In mechanism studies, 6a inhibited tubulin polymerization and disorganized microtubule in A549 cells by binding to tubulin colchicine binding site, indicating its in vivo potential as anticancer agent.
Journal ArticleDOI
The development of MetAP-2 inhibitors in cancer treatment.
TL;DR: Reversible human MetAP-2 inhibitors, such as bengamides, 2-hydroxy-3-aminoamides and triazole analogs, have demonstrated their potential to inhibit angiogenesis and tumor growth in vivo as well.
Journal ArticleDOI
Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization
Kunkun Han,Xin Xu,Guodong Chen,Yuanying Zeng,Jingyu Zhu,Xiaolin Du,Zubin Zhang,Biyin Cao,Zhao-Peng Liu,Xinliang Mao +9 more
TL;DR: Because of its potent anti-MM activity, low toxicity, and easy synthesis, BENC-511 could be developed as a promising agent for the treatment of MM via suppressing the PI3K/AKT signaling pathway.